Entheon Biomedical Corp.
ENBI
CNSX
11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | 0.00 |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | 0.00 |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | 0.00 |
SG&A Expenses | 62.10K | 49.10K | 74.90K | 58.00K | 54.80K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 62.10K | 49.10K | 74.90K | 58.00K | 54.80K |
Operating Income | -62.10K | -49.10K | -74.90K | -58.00K | -54.80K |
Income Before Tax | -60.90K | -47.20K | -69.40K | -55.70K | -53.90K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -60.90K | -47.20K | -69.40K | -55.70K | -53.90K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -60.90K | -47.20K | -69.40K | -55.70K | -53.90K |
EBIT | -62.10K | -49.10K | -74.90K | -58.00K | -54.80K |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
Average Basic Shares Outstanding | 8.85M | 8.86M | 7.32M | 5.91M | 5.91M |
Average Diluted Shares Outstanding | 8.85M | 8.86M | 7.32M | 5.91M | 5.91M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |